Akero Therapeutics Company Leadership
| AKRO Stock | USD 32.17 1.01 3.24% |
Akero Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Akero Therapeutics suggests that virtually all insiders are panicking. Akero Therapeutics employs about 60 people. The company is managed by 9 executives with a total tenure of roughly 140 years, averaging almost 15.0 years of service per executive, having 6.67 employees per reported executive.
Akero Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-11-15 | Catriona Yale | Disposed 9061 @ 27.73 | View | ||
| 2024-11-01 | Andrew Cheng | Disposed 108366 @ 31.73 | View | ||
| 2024-10-30 | Catriona Yale | Disposed 4515 @ 32.53 | View | ||
| 2024-10-18 | Andrew Cheng | Disposed 63539 @ 31.53 | View | ||
| 2024-10-16 | Andrew Cheng | Disposed 24992 @ 31.14 | View | ||
| 2024-10-14 | Jonathan Young | Disposed 40000 @ 30.15 | View | ||
| 2024-10-01 | Jonathan Young | Disposed 10000 @ 28.18 | View | ||
| 2024-09-20 | Catriona Yale | Disposed 5500 @ 27.65 | View | ||
| 2024-09-18 | Catriona Yale | Disposed 3871 @ 27.56 | View | ||
| 2024-09-16 | Catriona Yale | Disposed 2485 @ 27.52 | View | ||
| 2024-09-10 | Andrew Cheng | Disposed 1738 @ 26.18 | View | ||
| 2024-08-26 | William Richard White | Disposed 75159 @ 27.21 | View | ||
| 2024-08-23 | Catriona Yale | Disposed 8851 @ 27.53 | View |
Monitoring Akero Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Akero |
Akero Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Akero Therapeutics' future performance. Based on our forecasts, it is anticipated that Akero will maintain a workforce of about 60 employees by December 2024.Akero Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2317) % which means that it has lost $0.2317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.359) %, meaning that it created substantial loss on money invested by shareholders. Akero Therapeutics' management efficiency ratios could be used to measure how well Akero Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.32. At this time, Akero Therapeutics' Total Assets are very stable compared to the past year. As of the 28th of November 2024, Net Tangible Assets is likely to grow to about 394.3 M, though Non Currrent Assets Other are likely to grow to (0.95).As of the 28th of November 2024, Common Stock Shares Outstanding is likely to drop to about 34.6 M. In addition to that, Net Loss is likely to drop to about (105.9 M)
Akero Therapeutics Workforce Comparison
Akero Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 2,492. Akero Therapeutics holds roughly 60.0 in number of employees claiming about 2.41% of equities under Health Care industry.
Akero Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akero Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akero Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Akero Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 0.3871 | 12 | 31 | 330,541 | 682,218 |
| 2024-09-01 | 0.381 | 16 | 42 | 343,423 | 629,392 |
| 2024-06-01 | 1.3 | 13 | 10 | 411,477 | 34,015 |
| 2024-03-01 | 0.3333 | 6 | 18 | 218,967 | 319,299 |
| 2023-12-01 | 1.0455 | 23 | 22 | 1,661,829 | 149,657 |
| 2023-09-01 | 0.4545 | 10 | 22 | 580,745 | 190,514 |
| 2023-06-01 | 0.5758 | 19 | 33 | 623,500 | 555,683 |
| 2023-03-01 | 0.1481 | 4 | 27 | 83,777 | 276,839 |
| 2022-12-01 | 0.4762 | 30 | 63 | 1,046,755 | 2,279,752 |
| 2022-09-01 | 1.0 | 8 | 8 | 546,296 | 137,500 |
| 2022-03-01 | 0.6 | 6 | 10 | 120,444 | 150,144 |
| 2021-12-01 | 0.6 | 9 | 15 | 626,846 | 122,600 |
| 2021-09-01 | 0.2353 | 4 | 17 | 28,500 | 171,500 |
| 2021-06-01 | 0.6429 | 9 | 14 | 145,200 | 6,024,545 |
| 2021-03-01 | 0.2 | 2 | 10 | 27,500 | 56,670 |
| 2020-12-01 | 1.1667 | 7 | 6 | 570,800 | 36,530 |
| 2020-09-01 | 0.6667 | 2 | 3 | 830,000 | 116,467 |
| 2020-06-01 | 10.0 | 10 | 1 | 71,225 | 26,000 |
| 2020-03-01 | 0.2131 | 13 | 61 | 192,095 | 2,655,429 |
| 2019-12-01 | 0.7059 | 12 | 17 | 655,742 | 1,668,004 |
| 2019-06-01 | 0.6286 | 22 | 35 | 31,538,498 | 92,335,556 |
Akero Therapeutics Notable Stakeholders
An Akero Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Akero Therapeutics often face trade-offs trying to please all of them. Akero Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Akero Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Dr JD | Executive CoFounder | Profile | |
| Andrew MD | CEO President | Profile | |
| Timothy Rolph | CoFounder Officer | Profile | |
| Patrick Lamy | Senior Strategy | Profile | |
| Scott Gangloff | Chief Officer | Profile | |
| Catriona Yale | Executive Officer | Profile | |
| William JD | CFO, VP | Profile | |
| David JD | Vice Legal | Profile | |
| John Schembri | Senior Finance | Profile |
About Akero Therapeutics Management Performance
The success or failure of an entity such as Akero Therapeutics often depends on how effective the management is. Akero Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Akero management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Akero management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.26) | (0.27) | |
| Return On Capital Employed | (0.31) | (0.32) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.28) | (0.27) |
Akero Therapeutics Workforce Analysis
Traditionally, organizations such as Akero Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Akero Therapeutics within its industry.Akero Therapeutics Manpower Efficiency
Return on Akero Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.5M | |
| Net Loss Per Executive | 16.9M | |
| Working Capital Per Employee | 9M | |
| Working Capital Per Executive | 60.1M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.78) | Return On Assets (0.23) | Return On Equity (0.36) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.